The evaluation of gamma-glutamylcyclotransferase as a novel target for cancer therapy and diagnosis

γ-谷氨酰环转移酶作为癌症治疗和诊断新靶点的评估

• 批准号: nhmrc : 525458
• 负责人: Prof Philip Board
• 金额: $ 28.93万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/evaluation-gamma-glutamylcyclotransferase-therapy-diagnosis/82457
• 关键词: evaluation; gamma; glutamylcyclotransferase; novel; target

Gamma glutamylcyclotransferase (GGCT) plays a pivotal role in regulating the synthesis of glutathione, a compound that is essential for life and regulates many intracellular processes. Several recent studies have shown that GGCT is highly expressed in cancer cells . This study will determine if GGCT is a target for cancer chemotherapy or if it can be used for cancer diagnosis. This study may also provide a new treatment for patients with glutathione synthetase deficiency.

谷氨酰环转移酶（GGCT）在调节谷胱甘肽的合成中起关键作用，谷胱甘肽是一种对生命至关重要的化合物，并调节许多细胞内过程。最近几项研究表明，GGCT在癌细胞中高度表达。这项研究将确定GGCT是否是癌症化疗的靶点，或者是否可以用于癌症诊断。本研究也可能为谷胱甘肽合成酶缺乏症患者提供一种新的治疗方法。